Other groups are exploring the association between variants in PNPLA3-TM6SF2-GCKR-MBOAT7 in order to design polygenic risk scores (PRS) that can be evaluated in the clinic to gain insight into the causal relationship between NAFLD and hepatocellular carcinoma (HCC) and to stratify risk of HCC. This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatotic liver disease.